Literature DB >> 2655004

Gastrinomas: comparison of MR imaging with CT, angiography, and US.

H Frucht1, J L Doppman, J A Norton, D L Miller, A J Dwyer, J A Frank, R Vinayek, P N Maton, R T Jensen.   

Abstract

In this prospective study, magnetic resonance (MR) imaging was used to localize gastrinoma in 24 patients with Zollinger-Ellison syndrome. The results were confirmed by means of either surgery or percutaneous liver biopsy and compared with results of computed tomographic (CT) scanning, selective abdominal angiography, and abdominal ultrasound (US). For primary extrahepatic gastrinoma (intra-or extrapancreatic), MR imaging had a sensitivity of 20% and a specificity of 100%, with a positive predictive value of 100% and a negative predictive value of 11%. For metastatic gastrinoma in the liver, MR imaging had a sensitivity of 43% and a specificity of 100%, with a positive predictive value of 100% and a negative predictive value of 81%. The ability of MR imaging to depict extrahepatic gastrinomas was directly related to tumor size; no tumors smaller than 1 cm were detected, and 50% of tumors 3 cm or larger were detected. MR imaging was as effective as abdominal US but less effective than either CT scanning or selective abdominal angiography for the detection of extrahepatic gastrinoma. In seven patients with hepatic gastrinoma, three gastrinomas were detected with MR imaging and with abdominal US, while five were detected with CT scanning and with selective abdominal angiography. These results indicate that, at the present time, MR imaging is generally not useful in the initial attempt to localize gastrinomas.

Entities:  

Mesh:

Year:  1989        PMID: 2655004     DOI: 10.1148/radiology.171.3.2655004

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  34 in total

Review 1.  Unresolved surgical issues in the management of patients with Zollinger-Ellison syndrome.

Authors:  J A Norton; R T Jensen
Journal:  World J Surg       Date:  1991 Jan-Feb       Impact factor: 3.352

Review 2.  Imaging of neuroendocrine tumors of the pancreas.

Authors:  J L Fidler; C D Johnson
Journal:  Int J Gastrointest Cancer       Date:  2001

Review 3.  Localization of gastrinomas.

Authors:  R A Prinz
Journal:  Int J Pancreatol       Date:  1996-04

4.  Original oblique sections of the retroperitoneum: radio-anatomic basis.

Authors:  P Chaffanjon; S Mollier; J F Le Bas; J Champetier
Journal:  Surg Radiol Anat       Date:  1995       Impact factor: 1.246

5.  [Clinical value of somatostatin receptor scintigraphy. Studies of pre- and intraoperative localization of gastrointestinal and pancreatic tumors].

Authors:  S Adams; R P Baum; M Adams; H J Wenisch; P M Schumm-Draeger; A Encke; K H Usadel; G Hör
Journal:  Med Klin (Munich)       Date:  1997-03-15

6.  The Zollinger-Ellison syndrome. A collective surgical experience.

Authors:  D R Farley; J A van Heerden; C S Grant; L J Miller; D M Ilstrup
Journal:  Ann Surg       Date:  1992-06       Impact factor: 12.969

7.  Localisation of neuroendocrine tumours of the upper gastrointestinal tract.

Authors:  T Zimmer; K Ziegler; M Bäder; U Fett; B Hamm; E O Riecken; B Wiedenmann
Journal:  Gut       Date:  1994-04       Impact factor: 23.059

8.  Gastrinomas: a 42-year experience.

Authors:  E L Kaplan; K Horvath; A Udekwu; F Straus; C Schark; D J Ferguson; D B Skinner
Journal:  World J Surg       Date:  1990 May-Jun       Impact factor: 3.352

9.  A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors.

Authors:  Marc J Berna; Bruno Annibale; Massimo Marignani; Tu Vinh Luong; Vito Corleto; Andrea Pace; Tetsuhide Ito; David Liewehr; David J Venzon; Gianfranco Delle Fave; Cesare Bordi; Robert T Jensen
Journal:  J Clin Endocrinol Metab       Date:  2008-02-12       Impact factor: 5.958

Review 10.  Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.

Authors:  David C Metz; Robert T Jensen
Journal:  Gastroenterology       Date:  2008-08-12       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.